“Biosimilar” Naming Conventions Should Not Be Addressed By WHO, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Changes to WHO's international non-proprietary names system could jeopardize the public health benefits of the current process, FDA argues.
You may also be interested in...
Follow-On Biologics Bill From Rep. Waxman To Be Introduced This Year
Legislation would allow FDA to take a “case-by-case” approach to approving generic versions of BLAs.
Follow-On Biologics Bill From Rep. Waxman To Be Introduced This Year
Legislation would allow FDA to take a “case-by-case” approach to approving generic versions of BLAs.
Just A Product, Not A Pathway, FDA Says Of Omnitrope Approval
Sandoz' follow-on human growth hormone does not establish a precedent for follow-on proteins for biologics regulated under the Public Health Service Act.